Published in Infect Immun on March 01, 2003
Comparative genomic hybridization analysis of Enterococcus faecalis: identification of genes absent from food strains. J Bacteriol (2006) 1.23
The transcriptome of the nosocomial pathogen Enterococcus faecalis V583 reveals adaptive responses to growth in blood. PLoS One (2009) 1.15
The extracytoplasmic function sigma factor SigV plays a key role in the original model of lysozyme resistance and virulence of Enterococcus faecalis. PLoS One (2010) 1.04
Role of methionine sulfoxide reductases A and B of Enterococcus faecalis in oxidative stress and virulence. Infect Immun (2010) 1.03
SlyA is a transcriptional regulator involved in the virulence of Enterococcus faecalis. Infect Immun (2011) 1.01
Redox balance via lactate dehydrogenase is important for multiple stress resistance and virulence in Enterococcus faecalis. Infect Immun (2013) 0.87
In vivo assessment of growth and virulence gene expression during commensal and pathogenic lifestyles of luxABCDE-tagged Enterococcus faecalis strains in murine gastrointestinal and intravenous infection models. Appl Environ Microbiol (2013) 0.85
CspR, a cold shock RNA-binding protein involved in the long-term survival and the virulence of Enterococcus faecalis. J Bacteriol (2012) 0.80
Bioactivity Studies of β-Lactam Derived Polycyclic Fused Pyrroli-Dine/Pyrrolizidine Derivatives in Dentistry: In Vitro, In Vivo and In Silico Studies. PLoS One (2015) 0.75
Histopathological changes induced in an animal model by potentially pathogenic Enterococcus faecalis strains recovered from ready-to-eat food outlets in Osun State, Nigeria. Infect Drug Resist (2015) 0.75
Functional studies of E. faecalis RNase J2 and its role in virulence and fitness. PLoS One (2017) 0.75
A genomic virulence reference map of Enterococcus faecalis reveals an important contribution of phage03-like elements in nosocomial genetic lineages to pathogenicity in a Caenorhabditis elegans infection model. Infect Immun (2015) 0.75
Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes. J Bacteriol (1974) 20.17
Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med (1993) 17.01
The life and times of the Enterococcus. Clin Microbiol Rev (1990) 16.58
Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science (1993) 14.91
Evidence for a chromosome-borne resistance transposon (Tn916) in Streptococcus faecalis that is capable of "conjugal" transfer in the absence of a conjugative plasmid. J Bacteriol (1981) 11.15
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis (1999) 10.30
Genetics of resistance to infection with Salmonella typhimurium in mice. J Infect Dis (1976) 5.92
Modification of Streptococcus faecalis sex pheromones after acquisition of plasmid DNA. Proc Natl Acad Sci U S A (1983) 5.27
Virulence of enterococci. Clin Microbiol Rev (1994) 4.32
Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice. J Immunol (1981) 3.95
The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J Exp Med (1995) 3.86
Hemolysin of Streptococcus faecalis subspecies zymogenes contributes to virulence in mice. Infect Immun (1984) 3.83
Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein. Infect Immun (1999) 3.34
Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model. J Infect Dis (1998) 3.28
Effects of Enterococcus faecalis fsr genes on production of gelatinase and a serine protease and virulence. Infect Immun (2000) 3.15
Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect Immun (1992) 2.69
In vivo testing of an Enterococcus faecalis efaA mutant and use of efaA homologs for species identification. FEMS Immunol Med Microbiol (1998) 2.21
Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) (1988) 2.09
Enterococcal endocarditis. Clin Infect Dis (1992) 2.04
Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control (1989) 1.98
Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis. Infect Immun (2000) 1.91
Control of early Salmonella typhimurium growth in innately Salmonella-resistant mice does not require functional T lymphocytes. J Immunol (1982) 1.90
Enterococcal bacteremia without endocarditis. Arch Intern Med (1981) 1.85
Cellular mechanisms of genetically controlled host resistance to Mycobacterium bovis (BCG). J Immunol (1983) 1.81
Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med (1992) 1.76
Differential expression of virulence-related genes in Enterococcus faecalis in response to biological cues in serum and urine. Infect Immun (2002) 1.68
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother (1996) 1.68
Regulation of resistance to leprosy by chromosome 1 locus in the mouse. Immunogenetics (1984) 1.63
Hospital-acquired infectious endocarditis not associated with cardiac surgery: an emerging problem. Clin Infect Dis (1995) 1.61
Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia. Clin Infect Dis (2001) 1.59
Nosocomial bloodstream infections: organisms, risk factors, and implications. Clin Infect Dis (2000) 1.55
Infection genomics: Nramp1 as a major determinant of natural resistance to intracellular infections. Annu Rev Med (1998) 1.52
Involvement of PhoP-PhoS homologs in Enterococcus faecalis virulence. Infect Immun (2002) 1.46
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob Agents Chemother (1995) 1.40
In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother (1995) 1.38
Regulation of host resistance to Mycobacterium intracellulare in vivo and in vitro by the Bcg gene. Immunogenetics (1989) 1.35
Enterococcal bacteremia: clinical implications and determinants of death. Ann Surg (1982) 1.30
Augmented production of extracellular superoxide by blood isolates of Enterococcus faecalis. J Infect Dis (1996) 1.27
Survival of Enterococcus faecalis in mouse peritoneal macrophages. Infect Immun (1999) 1.25
Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis. Antimicrob Agents Chemother (1990) 1.10
Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin Infect Dis (1992) 1.08
Frequency of aggregation substance and cytolysin genes among enterococcal endocarditis isolates. Plasmid (1995) 1.08
High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis (1991) 1.07
The hemolysin/bacteriocin produced by enterococci is a marker of pathogenicity. Diagn Microbiol Infect Dis (1992) 1.04
Synthesis and antibacterial activity of N-acyl vancomycins. J Antibiot (Tokyo) (1988) 1.02
Clinical significance of enterococci in blood cultures from adult patients. Infection (1980) 1.01
Transfer of innate resistance and susceptibility to Leishmania donovani infection in mouse radiation bone marrow chimaeras. Immunology (1984) 0.95
Case-control study of risk factors for the development of enterococcal bacteremia. Eur J Clin Microbiol Infect Dis (2001) 0.90
Clinical and molecular epidemiology of Enterococcus faecalis bacteremia, with special reference to strains with high-level resistance to gentamicin. Clin Infect Dis (1995) 0.86
In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 0.84
Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas. J Clin Microbiol (1998) 0.83
Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection. J Antimicrob Chemother (2000) 0.81
In-vitro and in-vivo antibacterial activity of LB10517, a novel catechol-substituted cephalosporin with a broad antibacterial spectrum. J Antimicrob Chemother (1996) 0.77
Experimental infection of horses with West Nile virus. Emerg Infect Dis (2002) 1.81
Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther (2011) 1.09
Identification of genes associated with survival of Salmonella enterica serovar Enteritidis in chicken egg albumen. Appl Environ Microbiol (2006) 1.08
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther (2012) 0.94
Femoral component revision using an extensively hydroxyapatite-coated stem. J Arthroplasty (2004) 0.86
Fulkerson procedure for chronic patella component dislocation after total knee arthroplasty. J Arthroplasty (2008) 0.78
Unusual observation of hemorrhage within the myocardium and myopathy of the heart. Toxicol Pathol (2008) 0.75
Impaction grafting for femoral component revision using a non-polished bead-blasted chrome cobalt stem-average 8 1/2-year follow-up. J Arthroplasty (2006) 0.75